A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age

Abstract

Background: Epidemiologic studies indicate that individuals with germline BRCA mutation (gBRCAm) status are diagnosed with breast cancer at a median age of 40-45, which is approximately 20 yrs younger than the overall breast cancer population. Talazoparib (TALA), a highly potent PARP inhibitor that causes cell death in BRCA1/2-mutated cells, may have treatment potential in this younger population.